RTI Health Solutions®

Biometrics: Oncology Data Analytics

Experience in oncology data analysis to support regulatory, payer, and promotional positioning

Our Biometrics group has broad experience with analytical techniques in outcomes research. We can help you develop value messages and successfully develop and commercialize your products.

We understand the special challenges associated with analysis of endpoints in oncology clinical trials and other sources. We routinely provide the link between our clients' clinical statistics and outcomes research groups. We are GCP-compliant and provide high-quality, auditable tables for submissions.

Our deliverables often directly lead to additional analyses for publications. The result is faster development of supplementary evidence to support value messages for regulatory submissions and payer discussions.

We have conducted studies across the clinical development lifecycle for numerous cancer types, including breast, colorectal, bladder, renal cell, NSCLC, ovarian, prostate, lung, gastric, and head and neck cancers.

We help you develop and commercialize your products with our wide range of analytic expertise and deliverables.



(continued)

Contact

RTI Health Solutions
Research Triangle Park, NC, USA
+1.800.262.3011

Ann Arbor, MI, USA
+1.734.213.5372

Barcelona, Spain
+34.93.241.7766

Lund, Sweden
+46.706.58.3442

Manchester, UK
+44(0)161.232.3400

Sheffield, UK
+44(0)114.213.3390

Waltham, MA, USA
+1.781.434.1700

rtihealthsolutions@rti.org
www.rtihs.org

RTI Health Solutions Key Thought Leaders

Beth Sherrill, MS

Global Head, Biometrics
bsherrill@rti.org

Neil Roskell, MSc

Director, Biometrics
nroskell@rti.org
Manchester, UK

Rely On Our Thought Leaders

We are adept with data from multiple sources and experienced in complex analytical techniques including mixed models, pattern-mixture, propensity scoring, and sample weighting. We select and implement state-of-the-art analytical methodologies based on project requirements and the type of data.

The broad study experience and expert use of survival techniques makes us particularly well-suited for exploring post-hoc requests from oncology clinical trial data, including analyses of subgroups, QOL and healthcare utilization data.

See How We've Helped Others

An Observational Cohort Study of Patients with HER2-Positive Metastatic Breast Cancer

RTI-HS is the statistical coordinating center for a large multi-year patient registry. Our client selected RTI-HS based on our biostatistical expertise and experience with the special challenges associated with observational studies. RTI-HS planned the routine analysis reports and implements hypothesis-driven analyses. Over the past 5 years, RTI-HS statisticians have participated on the external advisory board and collaborated with the company in presenting data at internal and external scientific meetings.

Analyses of Quality-of-Life for New Chemotherapy

RTI-HS statisticians performed a series of analyses on QOL data from clinical trials for a new chemotherapeutic agent. Treatment outcomes and toxicities were evaluated simultaneously using the survival-based Q-TWiST approach. RTI-HS provided supplemental support to regulatory applications, and the work led to multiple posters at breast cancer conferences such as ASCO, SABCS, and EBCC. Results were published in Current Medical Research & Opinion 2010;26(4):767-75 and (5):1065-73 and Breast Cancer Research and Treatment 2009;117(3):577-89.

Meta-Analysis on the Relationship Between Progression and Survival in Metastatic Breast Cancer

RTI-HS performed a meta-analysis to assess the association between time to disease progression and overall survival in metastatic breast cancer studies based on a systematic literature review. Results were published in British Journal of Cancer 2008; 99(10):1572-78.

Meta-Analysis to Estimate the Association Between Asthma and Cancer Incidence

We searched the National Library of Medicine Gateway to identify observational studies of cancer incidence in asthma and included any case-control or cohort study of incident cancers or of cancer mortality that met the predefined inclusion criteria. The study found no significant association between asthma and cancer incidence. Results were published in Annals of Allergy Asthma and Immunology 2005;95(4):354-60.

Let RTI-HS Help You

To learn more about our capabilities, please visit us online at www.rtihs.org, e-mail us at rtihealthsolutions@rti.org, or contact one of our experts.

FS.BIOMETRICS ODA.0610